Tousignant Jennifer
SEC CIK 2010978 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| VRDN | Viridian Therapeutics, Inc.\DE | CLO | 0 | — | $419.0K | 6 | 2025-12-31 | 2026-08-19 |
Most active insiders at VRDN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Fairmount Funds Management LLC | Dir, 10% | $20.00M | — |
| 2 | Fairmount Healthcare Fund II GP LLC | Dir, 10% | $10.00M | — |
| 3 | Tousignant Jennifer | CLO | — | $419.0K |
| 4 | Harmon Seth | CFO | — | — |
| 5 | Tripuraneni Radhika | Chief Medical Off | — | — |
| 6 | Mahoney Stephen F. | Pres, CEO, Dir | — | — |
| 7 | Beetham Thomas W. | COO | — | — |
Transactions 6
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-08-20 20:05 | 2026-08-19 | VRDN | Viridian Therapeutics, Inc.\DE | Tousignant Jennifer | CLO | S - Sale+OE | $24.50 | -14.2K | 0 | -100% | -$348.2K |
| D | 2026-08-20 20:05 | 2026-08-19 | VRDN | Viridian Therapeutics, Inc.\DE | Tousignant Jennifer | CLO | M - OptEx | $14.41 | +10.0K | 10.0K | New | +$144.1K |
| A | 2026-03-09 | 2026-03-03 | VRDN | Viridian Therapeutics, Inc.\DE | Tousignant Jennifer | CLO | F - Tax | $30.19 | -1,675 | 3,494 | -32% | -$50.6K |
| D | 2026-03-04 | 2026-03-03 | VRDN | Viridian Therapeutics, Inc.\DE | Tousignant Jennifer | CLO | M - OptEx | — | +5,169 | 5,169 | New | — |
| D | 2026-03-04 | 2026-03-03 | VRDN | Viridian Therapeutics, Inc.\DE | Tousignant Jennifer | CLO | F - Tax | $29.32 | -1,724 | 3,445 | -33% | -$50.5K |
| 2026-01-02 | 2025-12-31 | VRDN | Viridian Therapeutics, Inc.\DE | Tousignant Jennifer | CLO | S - Sale | $31.16 | -2,272 | 0 | -100% | -$70.8K |
Purchase Sale Sale after option exercise All abbreviations